



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31 st Mar ' 2019

PART - I		Rs. in Lakhs							
Sl. No.	PARTICULARS	For the Quarter Ended			For the year Ended		Consolidated For the year Ended		
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018	31/03/2019	31/03/2018	
		Audited	Un-Audited	Audited	Audited	Audited	Audited	Audited	
1	Income								
	Revenue from operations	25,329.94	12,902.10	21,372.33	66,350.44	62,525.84	66,350.44	62,525.84	
	Other Income	375.33	576.20	922.60	2,422.93	2,327.07	2,422.93	2,327.07	
	Total income	25,705.27	13,478.30	22,294.93	68,773.37	64,852.91	68,773.37	64,852.91	
2	Expenses								
	a) Cost of materials consumed	6,235.09	6,217.04	4,483.78	20,413.82	17,616.48	20,413.82	17,616.48	
	b) Purchases of stock-in-trade	-	-	-	-	-	-	-	
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,302.19	(3,434.32)	1,482.12	(3,061.41)	(2,120.13)	(3,061.41)	(2,120.13)	
	d) Employee benefits expense	1,739.22	1,495.42	1,557.92	6,347.79	5,873.83	6,612.45	6,126.91	
	e) Finance costs	157.49	52.94	125.36	376.31	461.11	377.38	462.78	
	f) Depreciation and amortisation expense	546.26	560.93	536.14	2,214.05	2,130.99	2,214.05	2,130.99	
	g) Manufacturing Exps	2,499.40	2,704.36	2,150.75	9,982.32	8,695.35	9,982.32	8,695.35	
	h) R & D Exps	1,786.89	1,403.11	1,691.51	6,027.60	5,846.66	11,985.07	9,021.54	
	i) Other Expenses	1,237.68	956.81	882.03	4,286.59	3,322.05	4,375.37	3,366.40	
	Total expenses	15,504.22	9,956.29	12,909.61	46,587.07	41,826.34	52,899.05	45,300.32	
3	Profit before exceptional items & Tax (1-2)	10,201.05	3,522.01	9,385.32	22,186.30	23,026.57	15,874.32	19,552.59	
4	Exceptional Items	-	-	-	-	-	-	-	
5	Profit before Tax (3-4)	10,201.05	3,522.01	9,385.32	22,186.30	23,026.57	15,874.32	19,552.59	
6	Tax Expenses								
	a) Current tax	2,143.99	697.27	2,016.93	4,604.23	4,756.49	4,604.23	4,756.49	
	b) Deferred tax	1,259.22	301.47	1,117.28	2,575.78	2,427.35	2,575.78	2,427.35	
7	Net Profit/ (Loss) for the period/year(5-6)	6,797.84	2,523.27	6,251.11	15,006.29	15,842.73	8,694.31	12,368.75	
8	Other Comprehensive Income								
8.a	(i) Items that will not be reclassified to profit or loss	10.59	(10.58)	(31.15)	(21.16)	(42.33)	(21.16)	(42.33)	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3.70)	3.76	10.78	7.39	14.65	7.39	14.65	
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	
	Total other Comprehensive Income	6.89	(6.82)	(20.37)	(13.77)	(27.68)	(13.77)	(27.68)	
9	Total Comprehensive Income for the period (7+8)	6,804.73	2,516.45	6,230.74	14,992.52	15,815.05	8,680.54	12,341.07	
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	
11	Other Equity				98,088.00	85,397.16	81,826.56	75,467.82	
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :								
	a) Basic	5.34	1.98	4.91	11.79	12.45	6.83	9.72	
	b) Diluted	5.34	1.98	4.91	11.79	12.45	6.83	9.72	
		(not annualised)	(not annualised)	(not annualised)					

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES								Rs. In Lakhs
PARTICULARS	For the Quarter Ended			For the year Ended		Consolidated For the year Ended		
	31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018	31/03/2019	31/03/2018	
	Audited	Un-Audited	Audited	Audited	Audited	Audited	Audited	
1	SEGMENT REVENUE :-							
a) Manufacturing (CRAMS)	23,742.62	11,508.11	20,636.53	61,362.91	59,687.64	61,362.91	59,687.64	
b) Services (DDDSS)	1,587.32	1,393.99	735.80	4,987.53	2,838.20	4,987.53	2,838.20	
c) Research & Development	-	-	-	-	-	-	-	
TOTAL	25,329.94	12,902.10	21,372.33	66,350.44	62,525.84	66,350.44	62,525.84	
Less Inter segment Revenue	-	-	-	-	-	-	-	
Net Sales from Operations	25,329.94	12,902.10	21,372.33	66,350.44	62,525.84	66,350.44	62,525.84	
2	SEGMENT RESULTS :-							
Profit/(Loss) before tax and interest:								
a) Manufacturing (CRAMS)	12,117.59	4,138.53	10,492.63	26,594.91	28,031.87	26,330.25	27,778.79	
b) Services (DDDSS)	570.44	785.85	436.40	2,558.00	1,428.77	2,551.33	1,426.76	
c) Research & Development	(1,786.89)	(1,403.11)	(1,691.51)	(6,027.60)	(5,846.66)	(11,985.07)	(9,021.55)	
TOTAL	10,901.14	3,521.27	9,237.52	23,125.31	23,613.98	16,896.51	20,184.00	
Less: i) Interest	69.59	31.17	47.88	199.02	281.59	199.02	281.59	
ii) Other Un-allocable expenditure/(Income), net	630.50	(31.91)	(195.68)	739.99	305.82	823.17	349.82	
Total Profit Before Tax	10,201.05	3,522.01	9,385.32	22,186.30	23,026.57	15,874.32	19,552.59	
3	SEGMENT ASSETS :							
a) Manufacturing (CRAMS)	69,666.60	64,192.57	52,557.03	69,666.60	52,951.18	69,668.49	53,022.38	
b) Services (DDDSS)	5,687.52	5,755.22	4,061.14	5,687.52	4,000.97	5,687.52	3,931.57	
c) Research & Development	3,022.45	2,794.09	3,031.96	3,022.45	2,782.38	3,022.45	2,782.38	
d) Un allocated	39,125.31	41,584.05	41,234.30	39,125.31	41,713.11	25,510.28	32,179.61	
TOTAL	117,501.88	114,325.93	100,884.43	117,501.88	101,447.64	103,888.74	91,915.94	
	SEGMENT LIABILITIES :							
a) Manufacturing (CRAMS)	9,189.76	11,305.72	8,594.07	9,189.76	8,594.07	9,912.30	8,276.13	
b) Services (DDDSS)	641.72	690.10	382.64	641.72	382.64	688.83	366.08	
c) Research & Development	1,592.07	2,071.66	1,587.28	1,592.07	1,587.28	3,388.76	2,339.90	
d) Un allocated	829.03	1,053.78	714.79	829.03	1,194.03	910.98	1,173.54	
TOTAL	12,252.58	15,121.26	11,278.78	12,252.58	11,758.02	14,900.87	12,155.65	

1) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 25th May 2019 and the same reviewed by the Statutory Auditors.

2) Effective from 1st April 2018, the company has adopted Ind AS-115, "Revenue from contract with customers" using the cumulative effective method. The standard applied retrospectively only to contracts that are not completed as at the date of initial application and the comparative information is not restated in the statement of profit or loss, the adoption of the standard did not have any significant impact on the financial statements of the company.

3) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

4) The figures for the Qtr ended 31/03/2019 and Qtr ended 31/03/2018 are the balancing figures in respect of the full financial year and unaudited published year to date figures up to the third Qtr of the relevant financial year.

5) The Board of Directors in its meeting held on 5th February, 2019 approved the Scheme of Arrangement (Demerger) between Suven Life Sciences Ltd and Suven Pharmaceuticals Ltd. The Company received NOCs from BSE and NSE and is in the process of filing the application before NCLT Bench at Hyderabad.

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : 25th May ' 2019